US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Invivyd, Inc.

1.76

-0.1300-6.88%

Post-market: 1.72-0.0400-2.27%19:59 EDT

Volume:8.29M

Turnover:14.95M

Market Cap:377.36M

PE:-1.91

High:2.01

Open:2.00

Low:1.70

Close:1.89

52wk High:2.74

52wk Low:0.3546

Shares:214.41M

Float Shares:132.00M

Volume Ratio:0.68

T/O Rate:6.28%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.9194

EPS(LYR):-1.4333

ROE:-120.08%

ROA:-53.25%

PB:8.82

PE(LYR):-1.23

Loading ...

Overview Company News Filings

Invivyd Inc. Announces Rapid Pathway to Approval for COVID-19 Monoclonal Antibody VYD2311 Following FDA Alignment

Invivyd Aligns With U.S. FDA on Rapid Pathway to Full Approval (Bla) of Vaccine Alternative Monoclonal Antibody Vyd2311 to Protect American Adults and Adolescents From Covid-19

THOMSON REUTERS

The Race to Find a Measles Treatment as Infections Surge -- WSJ

Invivyd Inc expected to post a loss of 2 cents a share - Earnings Preview

Invivyd Inc. Launches SPEAR Study Group to Explore Monoclonal Antibody Therapy for Long COVID and Post-Vaccination Syndrome

Invivyd Is Maintained at Buy by D. Boral Capital

Invivyd Says Study Shows VYD2311 Well Tolerated as COVID-19 Drug Candidate

MT Newswires Live

BRIEF-Invivyd Announces Positive Full Phase 1/2 Clinical Data For Vyd2311

Invivyd Inc. Announces Upcoming FDA Meeting in Early Q3 to Discuss Regulatory Pathways for VYD2311 COVID-19 Monoclonal Antibodies

Invivyd Is Maintained at Buy by HC Wainwright & Co.

Invivyd's Pemgarda Added to NCCN Guidelines in Oncology for B-Cell Lymphomas

MT Newswires Live

Invivyd Inc. Engages FDA for Expedited Pathway on COVID-19 Monoclonal Antibody Development Amidst Regulatory Review

Invivyd Is Maintained at Buy by D. Boral Capital

Invivyd Inc reports results for the quarter ended March 31 - Earnings Summary

Invivyd Q1 EPS $(0.14) Up From $(0.38) YoY, Sales $11.30M Up from 0 YoY

Invivyd Inc. Reports Q1 2025 Results: PEMGARDA Revenue at $11.3M, Net Loss Reduced to $16.3M, EPS at $0.14

BRIEF-Invivyd Q1 EPS USD -0.14

Invivyd Urges US FDA to Focus on Monoclonal Antibodies for COVID-19 Prevention, Re-Assess Vaccine Efficacy

MT Newswires Live

Invivyd Inc expected to post a loss of 3 cents a share - Earnings Preview

BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers Health, TXNM Energy, Forge Global

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IVVD/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IVVD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IVVD\",,,,,undefined,":{"symbol":"IVVD","market":"US","secType":"STK","nameCN":"Invivyd, Inc.","latestPrice":1.76,"timestamp":1760126400000,"preClose":1.89,"halted":0,"volume":8285678,"hourTrading":{"tag":"盘后","latestPrice":1.72,"preClose":1.76,"latestTime":"19:59 EDT","volume":174247,"amount":295981.0177,"timestamp":1760140764851},"delay":0,"floatShares":132000000,"shares":214409450,"eps":-0.919406,"marketStatus":"Market Closed","change":-0.13,"latestTime":"10-10 16:00:00 EDT","open":2,"high":2.01,"low":1.7,"amount":14948488.307072401,"amplitude":0.164021,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.919406,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1760342400000},"marketStatusCode":7,"adr":0,"listingDate":1628222400000,"exchange":"NASDAQ","adjPreClose":1.89,"preHourTrading":{"tag":"盘前","latestPrice":1.99,"preClose":1.89,"latestTime":"09:27 EDT","volume":118128,"amount":231773.6094144,"timestamp":1760102870463},"postHourTrading":{"tag":"盘后","latestPrice":1.72,"preClose":1.76,"latestTime":"19:59 EDT","volume":174247,"amount":295981.0177,"timestamp":1760140764851},"volumeRatio":0.677733,"impliedVol":1.3274,"impliedVolPercentile":0.524},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IVVD\",,,,,undefined,":{"symbol":"IVVD","floatShares":132000000,"roa":"-53.25%","roe":"-120.08%","lyrEps":-1.4333,"volumeRatio":0.677733,"shares":214409450,"dividePrice":0,"high":2.01,"amplitude":0.164021,"preClose":1.89,"low":1.7,"week52Low":0.3546,"pbRate":"8.82","psRate":"8.17","week52High":2.74,"institutionHeld":0,"latestPrice":1.76,"eps":-0.919406,"divideRate":0,"volume":8285678,"delay":0,"ttmEps":-0.919406,"open":2,"prevYearClose":0.4431,"prevWeekClose":1.16,"prevMonthClose":1.1,"prevQuarterClose":1.1,"fiveDayClose":1.16,"twentyDayClose":1.43,"sixtyDayClose":0.7217},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IVVD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-14","symbol":"IVVD","fiscalQuarterEnding":"2025/06","expectedEps":-0.04,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.12},{"market":"US","date":"2025-05-15","symbol":"IVVD","fiscalQuarterEnding":"2025/03","expectedEps":-0.04,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.14},{"market":"US","date":"2025-03-20","symbol":"IVVD","fiscalQuarterEnding":"2024/12","expectedEps":-0.25,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742443200000,"reportTimeType":"pre","actualEps":-0.15},{"market":"US","date":"2025-02-03","symbol":"IVVD","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1738558800000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-11-14","symbol":"IVVD","fiscalQuarterEnding":"2024/09","expectedEps":-0.33,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"pre","actualEps":-0.51}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IVVD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IVVD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1730347200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IVVD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IVVD","date":"2025-10-09","current":-1.914279,"percent":0.158869,"low":-54.35026,"twenty":-2.549739,"median":-1.033598,"eighty":-0.605758,"high":-0.170743,"avg":-3.754382,"sd":8.658678,"marketCap":319724912},"quantilePoints":[{"date":"2021-08-06","current":-20.235974,"twenty":-12.209882,"median":-0.170743,"eighty":-0.170743,"marketCap":2265932260},{"date":"2021-08-13","current":-25.837695,"twenty":-26.477338,"median":-22.901153,"eighty":-8.196835,"marketCap":2893187455},{"date":"2021-08-20","current":-26.787468,"twenty":-26.857247,"median":-25.973377,"eighty":-21.081078,"marketCap":2999538682},{"date":"2021-08-27","current":-29.442955,"twenty":-27.834156,"median":-26.254432,"eighty":-22.790669,"marketCap":3296888030},{"date":"2021-09-03","current":-41.082517,"twenty":-30.582682,"median":-26.903767,"eighty":-24.407221,"marketCap":4600233167},{"date":"2021-09-10","current":-52.237501,"twenty":-34.346884,"median":-27.107289,"eighty":-25.864831,"marketCap":5849317474},{"date":"2021-09-17","current":-49.87276,"twenty":-41.574848,"median":-28.333272,"eighty":-25.990822,"marketCap":5584524623},{"date":"2021-09-24","current":-43.437403,"twenty":-45.837563,"median":-31.3425,"eighty":-26.070293,"marketCap":4863922575},{"date":"2021-10-01","current":-27.799143,"twenty":-45.332177,"median":-32.752622,"eighty":-26.167208,"marketCap":3112821446},{"date":"2021-10-08","current":-34.098162,"twenty":-44.772716,"median":-31.663999,"eighty":-26.477338,"marketCap":3818156971},{"date":"2021-10-15","current":-32.220379,"twenty":-44.391197,"median":-31.942189,"eighty":-26.810728,"marketCap":3607891333},{"date":"2021-10-22","current":-33.531847,"twenty":-43.143316,"median":-32.796234,"eighty":-26.944471,"marketCap":3754743525},{"date":"2021-10-29","current":-29.050998,"twenty":-41.908316,"median":-32.394248,"eighty":-27.107289,"marketCap":3252998538},{"date":"2021-11-05","current":-19.910465,"twenty":-41.574848,"median":-31.842835,"eighty":-27.107289,"marketCap":2229483266},{"date":"2021-11-12","current":-19.016283,"twenty":-41.160049,"median":-31.463508,"eighty":-26.167208,"marketCap":2129356772},{"date":"2021-11-19","current":-10.754495,"twenty":-40.958465,"median":-30.898976,"eighty":-23.930397,"marketCap":2232820816},{"date":"2021-11-26","current":-13.460534,"twenty":-40.462257,"median":-30.670462,"eighty":-19.910465,"marketCap":2794641699},{"date":"2021-12-03","current":-24.557973,"twenty":-40.277958,"median":-30.278016,"eighty":-20.235974,"marketCap":5098663577},{"date":"2021-12-10","current":-17.806272,"twenty":-39.274486,"median":-29.442955,"eighty":-19.910465,"marketCap":3696892661},{"date":"2021-12-17","current":-6.15155,"twenty":-36.830387,"median":-28.396375,"eighty":-19.016283,"marketCap":1277169056},{"date":"2021-12-23","current":-4.640455,"twenty":-35.773265,"median":-28.318734,"eighty":-17.731253,"marketCap":963439375},{"date":"2021-12-31","current":-3.890266,"twenty":-34.889434,"median":-27.107289,"eighty":-10.888458,"marketCap":807687051},{"date":"2022-01-07","current":-3.177586,"twenty":-34.726181,"median":-26.845617,"eighty":-10.250797,"marketCap":659722343},{"date":"2022-01-14","current":-3.054341,"twenty":-34.716142,"median":-26.109059,"eighty":-6.024018,"marketCap":634134462},{"date":"2022-01-21","current":-3.370492,"twenty":-34.344559,"median":-25.973377,"eighty":-4.803353,"marketCap":699772941},{"date":"2022-01-28","current":-3.633058,"twenty":-33.758373,"median":-25.150086,"eighty":-4.146402,"marketCap":754286254},{"date":"2022-02-04","current":-4.41004,"twenty":-33.472235,"median":-24.833935,"eighty":-4.117466,"marketCap":915601161},{"date":"2022-02-11","current":-3.750945,"twenty":-33.414609,"median":-22.901153,"eighty":-4.037089,"marketCap":778761620},{"date":"2022-02-18","current":-3.440152,"twenty":-33.038815,"median":-20.249744,"eighty":-3.881692,"marketCap":714235657},{"date":"2022-02-25","current":-3.499096,"twenty":-32.761344,"median":-19.910465,"eighty":-3.803458,"marketCap":726473339},{"date":"2022-03-04","current":-2.695322,"twenty":-32.644704,"median":-19.383891,"eighty":-3.620198,"marketCap":559595849},{"date":"2022-03-11","current":-2.706039,"twenty":-32.425048,"median":-19.016283,"eighty":-3.495881,"marketCap":561820883},{"date":"2022-03-18","current":-2.663171,"twenty":-32.232302,"median":-18.082234,"eighty":-3.447654,"marketCap":552920750},{"date":"2022-03-25","current":-2.121963,"twenty":-32.069361,"median":-13.460534,"eighty":-3.399428,"marketCap":440556573},{"date":"2022-04-01","current":-2.185863,"twenty":-31.771301,"median":-10.864345,"eighty":-3.292258,"marketCap":495731781},{"date":"2022-04-08","current":-1.866688,"twenty":-31.632206,"median":-10.454419,"eighty":-3.196877,"marketCap":423346167},{"date":"2022-04-14","current":-1.736117,"twenty":-31.536113,"median":-10.036457,"eighty":-2.990039,"marketCap":393733871},{"date":"2022-04-22","current":-1.426614,"twenty":-31.313407,"median":-6.874947,"eighty":-2.80142,"marketCap":323541760},{"date":"2022-04-29","current":-1.38309,"twenty":-31.137425,"median":-5.513889,"eighty":-2.691035,"marketCap":313670994},{"date":"2022-05-06","current":-1.392762,"twenty":-30.873144,"median":-5.106644,"eighty":-2.665314,"marketCap":315864498},{"date":"2022-05-13","current":-1.033486,"twenty":-30.749945,"median":-4.774417,"eighty":-2.440927,"marketCap":298425270},{"date":"2022-05-20","current":-1.120876,"twenty":-30.64463,"median":-4.321625,"eighty":-2.212136,"marketCap":323659760},{"date":"2022-05-27","current":-1.132275,"twenty":-30.523419,"median":-4.206417,"eighty":-2.074048,"marketCap":326951215},{"date":"2022-06-03","current":-1.200668,"twenty":-30.451885,"median":-4.15819,"eighty":-1.963408,"marketCap":346699946},{"date":"2022-06-10","current":-1.124676,"twenty":-30.104147,"median":-3.970643,"eighty":-1.784476,"marketCap":324756912},{"date":"2022-06-17","current":-1.033486,"twenty":-30.05447,"median":-3.890266,"eighty":-1.562021,"marketCap":298425270},{"date":"2022-06-24","current":-1.27695,"twenty":-29.565258,"median":-3.847398,"eighty":-1.481744,"marketCap":368726981},{"date":"2022-07-01","current":-1.330156,"twenty":-29.129389,"median":-3.775058,"eighty":-1.43822,"marketCap":384090605},{"date":"2022-07-08","current":-1.569584,"twenty":-28.687364,"median":-3.66253,"eighty":-1.432587,"marketCap":453226914},{"date":"2022-07-15","current":-1.527779,"twenty":-28.386662,"median":-3.584832,"eighty":-1.439301,"marketCap":441155495},{"date":"2022-07-22","current":-1.580986,"twenty":-28.330364,"median":-3.496417,"eighty":-1.441122,"marketCap":456519119},{"date":"2022-07-29","current":-1.337757,"twenty":-28.318734,"median":-3.466945,"eighty":-1.439301,"marketCap":386285408},{"date":"2022-08-05","current":-1.520179,"twenty":-28.006979,"median":-3.442832,"eighty":-1.418008,"marketCap":438960692},{"date":"2022-08-12","current":-1.516378,"twenty":-27.384031,"median":-3.402643,"eighty":-1.425167,"marketCap":437863290},{"date":"2022-08-19","current":-1.549068,"twenty":-27.107289,"median":-3.34102,"eighty":-1.426035,"marketCap":457088205},{"date":"2022-08-26","current":-1.69291,"twenty":-26.985176,"median":-3.279398,"eighty":-1.431485,"marketCap":499532109},{"date":"2022-09-02","current":-1.762987,"twenty":-26.833988,"median":-3.247247,"eighty":-1.435834,"marketCap":520209909},{"date":"2022-09-09","current":-1.696599,"twenty":-26.632403,"median":-3.150793,"eighty":-1.43839,"marketCap":500620415},{"date":"2022-09-16","current":-1.416291,"twenty":-26.283507,"median":-2.973964,"eighty":-1.43839,"marketCap":417909216},{"date":"2022-09-23","current":-1.095413,"twenty":-26.089676,"median":-2.842681,"eighty":-1.425167,"marketCap":323226659},{"date":"2022-09-30","current":-1.166035,"twenty":-26.025711,"median":-2.786416,"eighty":-1.403926,"marketCap":344065403},{"date":"2022-10-07","current":-1.188387,"twenty":-25.919104,"median":-2.692642,"eighty":-1.367291,"marketCap":350660906},{"date":"2022-10-14","current":-1.221915,"twenty":-25.585157,"median":-2.679246,"eighty":-1.335295,"marketCap":360554160},{"date":"2022-10-21","current":-1.370929,"twenty":-25.161339,"median":-2.598869,"eighty":-1.327097,"marketCap":404524180},{"date":"2022-10-28","current":-1.464063,"twenty":-25.020946,"median":-2.452181,"eighty":-1.331555,"marketCap":432005442},{"date":"2022-11-04","current":-1.318774,"twenty":-24.880554,"median":-2.304152,"eighty":-1.330032,"marketCap":389134673},{"date":"2022-11-11","current":-1.402279,"twenty":-24.72355,"median":-2.205207,"eighty":-1.330032,"marketCap":392336643},{"date":"2022-11-18","current":-1.071185,"twenty":-24.116213,"median":-2.120061,"eighty":-1.321288,"marketCap":299701602},{"date":"2022-11-25","current":-0.833577,"twenty":-23.232604,"median":-2.052303,"eighty":-1.304144,"marketCap":233222338},{"date":"2022-12-02","current":-0.903691,"twenty":-22.029676,"median":-1.963408,"eighty":-1.287526,"marketCap":252839170},{"date":"2022-12-09","current":-0.771253,"twenty":-20.652703,"median":-1.869106,"eighty":-1.273678,"marketCap":215785153},{"date":"2022-12-16","current":-0.631026,"twenty":-20.24699,"median":-1.781428,"eighty":-1.254406,"marketCap":176551489},{"date":"2022-12-23","current":-0.662187,"twenty":-20.170872,"median":-1.761143,"eighty":-1.246835,"marketCap":185270081},{"date":"2022-12-30","current":-0.584283,"twenty":-19.910465,"median":-1.729267,"eighty":-1.233091,"marketCap":163473601},{"date":"2023-01-06","current":-0.646606,"twenty":-19.910465,"median":-1.709507,"eighty":-1.220425,"marketCap":180910785},{"date":"2023-01-13","current":-0.864739,"twenty":-19.727655,"median":-1.700287,"eighty":-1.204982,"marketCap":241940930},{"date":"2023-01-20","current":-0.705035,"twenty":-19.324279,"median":-1.696599,"eighty":-1.18418,"marketCap":197258145},{"date":"2023-01-27","current":-0.966014,"twenty":-19.073908,"median":-1.680001,"eighty":-1.168577,"marketCap":270276354},{"date":"2023-02-03","current":-0.817996,"twenty":-19.036154,"median":-1.663404,"eighty":-1.145789,"marketCap":228863042},{"date":"2023-02-10","current":-0.697244,"twenty":-18.849703,"median":-1.652339,"eighty":-1.126955,"marketCap":195078497},{"date":"2023-02-17","current":-0.759568,"twenty":-18.510377,"median":-1.599988,"eighty":-1.120876,"marketCap":212515681},{"date":"2023-02-24","current":-0.669978,"twenty":-18.137426,"median":-1.580986,"eighty":-1.092453,"marketCap":187449729},{"date":"2023-03-03","current":-0.681663,"twenty":-17.656234,"median":-1.570639,"eighty":-1.028927,"marketCap":190719201},{"date":"2023-03-10","current":-0.689454,"twenty":-15.84292,"median":-1.562021,"eighty":-1.00081,"marketCap":192898849},{"date":"2023-03-17","current":-0.588178,"twenty":-12.481002,"median":-1.538592,"eighty":-0.965462,"marketCap":164563425},{"date":"2023-03-24","current":-0.592742,"twenty":-10.968835,"median":-1.527779,"eighty":-0.894342,"marketCap":143038670},{"date":"2023-03-31","current":-0.54297,"twenty":-10.872382,"median":-1.517437,"eighty":-0.884215,"marketCap":131027790},{"date":"2023-04-06","current":-0.538445,"twenty":-10.810224,"median":-1.510673,"eighty":-0.88032,"marketCap":129935891},{"date":"2023-04-14","current":-0.534538,"twenty":-10.69448,"median":-1.497376,"eighty":-0.857727,"marketCap":128993146},{"date":"2023-04-21","current":-0.539068,"twenty":-10.424412,"median":-1.489775,"eighty":-0.829682,"marketCap":130086308},{"date":"2023-04-28","current":-0.511888,"twenty":-10.250797,"median":-1.484646,"eighty":-0.81488,"marketCap":123527335},{"date":"2023-05-05","current":-0.534538,"twenty":-10.004306,"median":-1.471564,"eighty":-0.788392,"marketCap":128993146},{"date":"2023-05-12","current":-0.888336,"twenty":-9.42023,"median":-1.465302,"eighty":-0.768137,"marketCap":156322203},{"date":"2023-05-19","current":-0.777692,"twenty":-7.308984,"median":-1.45367,"eighty":-0.771253,"marketCap":136852082},{"date":"2023-05-26","current":-0.914566,"twenty":-6.075459,"median":-1.441122,"eighty":-0.771297,"marketCap":160938049},{"date":"2023-06-02","current":-0.933231,"twenty":-5.771097,"median":-1.436569,"eighty":-0.771471,"marketCap":164222499},{"date":"2023-06-09","current":-0.839908,"twenty":-5.513889,"median":-1.428574,"eighty":-0.777692,"marketCap":147800249},{"date":"2023-06-16","current":-0.796357,"twenty":-5.358493,"median":-1.425167,"eighty":-0.783914,"marketCap":140136532},{"date":"2023-06-23","current":-0.659483,"twenty":-5.277043,"median":-1.40727,"eighty":-0.771253,"marketCap":116050565},{"date":"2023-06-30","current":-0.703034,"twenty":-5.076636,"median":-1.402434,"eighty":-0.766514,"marketCap":123714282},{"date":"2023-07-07","current":-0.696812,"twenty":-4.903021,"median":-1.400732,"eighty":-0.759568,"marketCap":122619465},{"date":"2023-07-14","current":-0.858572,"twenty":-4.803353,"median":-1.392762,"eighty":-0.759568,"marketCap":151084699},{"date":"2023-07-21","current":-0.902123,"twenty":-4.720832,"median":-1.38309,"eighty":-0.76184,"marketCap":158748415},{"date":"2023-07-28","current":-0.902123,"twenty":-4.548289,"median":-1.369067,"eighty":-0.766093,"marketCap":158748415},{"date":"2023-08-04","current":-0.920788,"twenty":-4.339308,"median":-1.356759,"eighty":-0.767358,"marketCap":162032865},{"date":"2023-08-11","current":-0.964339,"twenty":-4.226779,"median":-1.354805,"eighty":-0.768916,"marketCap":169696582},{"date":"2023-08-18","current":-1.071184,"twenty":-4.212847,"median":-1.341126,"eighty":-0.771253,"marketCap":187682117},{"date":"2023-08-25","current":-1.115033,"twenty":-4.206417,"median":-1.331904,"eighty":-0.77134,"marketCap":195365010},{"date":"2023-09-01","current":-1.165147,"twenty":-4.187126,"median":-1.325058,"eighty":-0.771471,"marketCap":204145460},{"date":"2023-09-08","current":-1.108769,"twenty":-4.137828,"median":-1.318774,"eighty":-0.772715,"marketCap":194267454},{"date":"2023-09-15","current":-1.102505,"twenty":-4.046734,"median":-1.300575,"eighty":-0.778936,"marketCap":193169898},{"date":"2023-09-22","current":-1.039863,"twenty":-3.993149,"median":-1.292152,"eighty":-0.783914,"marketCap":182194335},{"date":"2023-09-29","current":-1.108769,"twenty":-3.92456,"median":-1.28265,"eighty":-0.784498,"marketCap":194267454},{"date":"2023-10-06","current":-1.02107,"twenty":-3.890266,"median":-1.27286,"eighty":-0.788392,"marketCap":178901667},{"date":"2023-10-13","current":-1.033598,"twenty":-3.885979,"median":-1.257306,"eighty":-0.794625,"marketCap":181096779},{"date":"2023-10-20","current":-0.989749,"twenty":-3.864545,"median":-1.253862,"eighty":-0.794971,"marketCap":173413885},{"date":"2023-10-27","current":-1.039863,"twenty":-3.855972,"median":-1.250062,"eighty":-0.795664,"marketCap":182194335},{"date":"2023-11-03","current":-0.970956,"twenty":-3.824892,"median":-1.24107,"eighty":-0.80009,"marketCap":170121217},{"date":"2023-11-10","current":-0.876993,"twenty":-3.803458,"median":-1.233091,"eighty":-0.803649,"marketCap":153657873},{"date":"2023-11-17","current":-0.974107,"twenty":-3.770235,"median":-1.223778,"eighty":-0.807025,"marketCap":165172440},{"date":"2023-11-24","current":-0.967613,"twenty":-3.727368,"median":-1.213951,"eighty":-0.8088,"marketCap":164071290},{"date":"2023-12-01","current":-0.993589,"twenty":-3.668424,"median":-1.20606,"eighty":-0.8088,"marketCap":168475888},{"date":"2023-12-08","current":-1.097493,"twenty":-3.624484,"median":-1.192112,"eighty":-0.81092,"marketCap":186094282},{"date":"2023-12-15","current":-1.116976,"twenty":-3.600907,"median":-1.17787,"eighty":-0.815659,"marketCap":189397731},{"date":"2023-12-22","current":-2.435267,"twenty":-3.563398,"median":-1.186164,"eighty":-0.817996,"marketCap":412931100},{"date":"2023-12-29","current":-2.545665,"twenty":-3.531247,"median":-1.195838,"eighty":-0.817996,"marketCap":431650643},{"date":"2024-01-05","current":-2.435267,"twenty":-3.511956,"median":-1.203364,"eighty":-0.820333,"marketCap":412931100},{"date":"2024-01-12","current":-2.688534,"twenty":-3.495881,"median":-1.213437,"eighty":-0.826566,"marketCap":455875934},{"date":"2024-01-19","current":-2.883356,"twenty":-3.48945,"median":-1.221915,"eighty":-0.829682,"marketCap":488910422},{"date":"2024-01-26","current":-2.876862,"twenty":-3.47659,"median":-1.233091,"eighty":-0.83124,"marketCap":487809272},{"date":"2024-02-02","current":-3.117141,"twenty":-3.460515,"median":-1.235593,"eighty":-0.833621,"marketCap":528551808},{"date":"2024-02-09","current":-3.272998,"twenty":-3.448726,"median":-1.249027,"eighty":-0.836175,"marketCap":554979398},{"date":"2024-02-16","current":-2.88069,"twenty":-3.448726,"median":-1.254147,"eighty":-0.839908,"marketCap":488458412},{"date":"2024-02-23","current":-2.831627,"twenty":-3.444439,"median":-1.259169,"eighty":-0.842397,"marketCap":480139169},{"date":"2024-03-01","current":-2.754528,"twenty":-3.436937,"median":-1.274905,"eighty":-0.852491,"marketCap":467066072},{"date":"2024-03-08","current":-2.670421,"twenty":-3.41979,"median":-1.284551,"eighty":-0.853832,"marketCap":452804513},{"date":"2024-03-15","current":-2.558277,"twenty":-3.401571,"median":-1.29463,"eighty":-0.857273,"marketCap":433789100},{"date":"2024-03-22","current":-2.165774,"twenty":-3.391926,"median":-1.301003,"eighty":-0.858572,"marketCap":367235156},{"date":"2024-03-28","current":-2.393164,"twenty":-3.370492,"median":-1.318774,"eighty":-0.858572,"marketCap":475385316},{"date":"2024-04-05","current":-2.148639,"twenty":-3.311549,"median":-1.327504,"eighty":-0.860844,"marketCap":426812003},{"date":"2024-04-12","current":-1.833545,"twenty":-3.311549,"median":-1.333653,"eighty":-0.864739,"marketCap":364220857},{"date":"2024-04-19","current":-1.410419,"twenty":-3.279398,"median":-1.341342,"eighty":-0.864794,"marketCap":280169890},{"date":"2024-04-26","current":-1.242369,"twenty":-3.274039,"median":-1.341126,"eighty":-0.864794,"marketCap":246787946},{"date":"2024-05-03","current":-1.422423,"twenty":-3.272998,"median":-1.339441,"eighty":-0.864794,"marketCap":282554315},{"date":"2024-05-10","current":-1.452432,"twenty":-3.268681,"median":-1.354074,"eighty":-0.871015,"marketCap":288515376},{"date":"2024-05-17","current":-1.412314,"twenty":-3.26001,"median":-1.355782,"eighty":-0.876993,"marketCap":292092013},{"date":"2024-05-24","current":-1.158674,"twenty":-3.225813,"median":-1.354074,"eighty":-0.877237,"marketCap":239634672},{"date":"2024-05-31","current":-1.043383,"twenty":-3.211609,"median":-1.341126,"eighty":-0.879703,"marketCap":215790426},{"date":"2024-06-07","current":-1.009596,"twenty":-3.192472,"median":-1.333025,"eighty":-0.88032,"marketCap":208802627},{"date":"2024-06-14","current":-0.98075,"twenty":-3.181982,"median":-1.330053,"eighty":-0.88032,"marketCap":202836837},{"date":"2024-06-21","current":-0.755755,"twenty":-3.174189,"median":-1.321916,"eighty":-0.87847,"marketCap":156303680},{"date":"2024-06-28","current":-0.692294,"twenty":-3.170792,"median":-1.318774,"eighty":-0.877188,"marketCap":143178944},{"date":"2024-07-05","current":-0.634603,"twenty":-3.142038,"median":-1.315549,"eighty":-0.864794,"marketCap":131247365},{"date":"2024-07-12","current":-0.674987,"twenty":-3.119885,"median":-1.301003,"eighty":-0.859935,"marketCap":139599470},{"date":"2024-07-15","current":-0.686525,"twenty":-3.118513,"median":-1.300575,"eighty":-0.858572,"marketCap":141985786},{"date":"2024-08-02","current":-0.68941,"twenty":-3.117141,"median":-1.300147,"eighty":-0.858572,"marketCap":142582365},{"date":"2024-08-09","current":-0.605758,"twenty":-3.097659,"median":-1.294588,"eighty":-0.848061,"marketCap":125281576},{"date":"2024-08-16","current":-0.60941,"twenty":-3.065189,"median":-1.28637,"eighty":-0.833577,"marketCap":124220340},{"date":"2024-08-23","current":-0.514541,"twenty":-3.055914,"median":-1.279565,"eighty":-0.817996,"marketCap":104882577},{"date":"2024-08-30","current":-0.517764,"twenty":-3.054341,"median":-1.273965,"eighty":-0.8088,"marketCap":105539512},{"date":"2024-09-06","current":-0.498896,"twenty":-3.052629,"median":-1.268761,"eighty":-0.804006,"marketCap":101693459},{"date":"2024-09-13","current":-0.673867,"twenty":-3.052201,"median":-1.254795,"eighty":-0.793067,"marketCap":137359030},{"date":"2024-09-20","current":-0.714885,"twenty":-3.043957,"median":-1.250062,"eighty":-0.776448,"marketCap":145720014},{"date":"2024-09-27","current":-0.60941,"twenty":-3.030682,"median":-1.247269,"eighty":-0.770474,"marketCap":124220340},{"date":"2024-10-04","current":-0.562884,"twenty":-3.005449,"median":-1.242369,"eighty":-0.759568,"marketCap":114736595},{"date":"2024-10-11","current":-0.529894,"twenty":-2.97914,"median":-1.234118,"eighty":-0.750739,"marketCap":108011974},{"date":"2024-10-18","current":-0.61527,"twenty":-2.95253,"median":-1.22564,"eighty":-0.739313,"marketCap":125414766},{"date":"2024-10-25","current":-0.57935,"twenty":-2.944451,"median":-1.213951,"eighty":-0.734142,"marketCap":118092933},{"date":"2024-10-31","current":-0.533292,"twenty":-2.934797,"median":-1.206537,"eighty":-0.729185,"marketCap":108704742},{"date":"2024-11-08","current":-0.585971,"twenty":-2.925172,"median":-1.195838,"eighty":-0.709709,"marketCap":119442635},{"date":"2024-11-15","current":-0.419997,"twenty":-2.922744,"median":-1.180905,"eighty":-0.703113,"marketCap":94556475},{"date":"2024-11-22","current":-0.371808,"twenty":-2.92249,"median":-1.17407,"eighty":-0.697071,"marketCap":83707301},{"date":"2024-11-29","current":-0.37117,"twenty":-2.91193,"median":-1.166035,"eighty":-0.69059,"marketCap":83563762},{"date":"2024-12-06","current":-0.303269,"twenty":-2.891149,"median":-1.165147,"eighty":-0.68557,"marketCap":68276832},{"date":"2024-12-13","current":-0.308104,"twenty":-2.88229,"median":-1.162672,"eighty":-0.679326,"marketCap":69365338},{"date":"2024-12-20","current":-0.228302,"twenty":-2.879159,"median":-1.158778,"eighty":-0.673873,"marketCap":51399010},{"date":"2024-12-27","current":-0.281805,"twenty":-2.876862,"median":-1.150014,"eighty":-0.673867,"marketCap":63444344},{"date":"2025-01-03","current":-0.255027,"twenty":-2.876862,"median":-1.146355,"eighty":-0.669978,"marketCap":57415696},{"date":"2025-01-10","current":-0.245198,"twenty":-2.874317,"median":-1.138593,"eighty":-0.663197,"marketCap":55202800},{"date":"2025-01-17","current":-0.233403,"twenty":-2.868171,"median":-1.132275,"eighty":-0.656796,"marketCap":52547324},{"date":"2025-01-24","current":-0.222245,"twenty":-2.85831,"median":-1.128781,"eighty":-0.646866,"marketCap":50035387},{"date":"2025-01-31","current":-0.207209,"twenty":-2.840038,"median":-1.124676,"eighty":-0.643039,"marketCap":46650253},{"date":"2025-02-07","current":-1.051985,"twenty":-2.823791,"median":-1.121298,"eighty":-0.64111,"marketCap":236839749},{"date":"2025-02-14","current":-0.733202,"twenty":-2.818476,"median":-1.120876,"eighty":-0.643039,"marketCap":165070128},{"date":"2025-02-21","current":-0.64288,"twenty":-2.812485,"median":-1.118477,"eighty":-0.643031,"marketCap":144735402},{"date":"2025-02-28","current":-0.658819,"twenty":-2.803591,"median":-1.116976,"eighty":-0.644411,"marketCap":148323883},{"date":"2025-03-07","current":-0.547245,"twenty":-2.801008,"median":-1.110663,"eighty":-0.636245,"marketCap":123204516},{"date":"2025-03-14","current":-0.431473,"twenty":-2.796913,"median":-1.108769,"eighty":-0.631096,"marketCap":97140182},{"date":"2025-03-21","current":-0.521427,"twenty":-2.792516,"median":-1.102505,"eighty":-0.62713,"marketCap":88603523},{"date":"2025-03-28","current":-0.43064,"twenty":-2.784875,"median":-1.097493,"eighty":-0.619015,"marketCap":73176481},{"date":"2025-04-04","current":-0.388282,"twenty":-2.77135,"median":-1.096241,"eighty":-0.613037,"marketCap":65978794},{"date":"2025-04-11","current":-0.356513,"twenty":-2.754107,"median":-1.09048,"eighty":-0.611536,"marketCap":60580529},{"date":"2025-04-17","current":-0.332722,"twenty":-2.752176,"median":-1.083864,"eighty":-0.609696,"marketCap":56537829},{"date":"2025-04-25","current":-0.471868,"twenty":-2.738793,"median":-1.080862,"eighty":-0.606488,"marketCap":80182229},{"date":"2025-05-02","current":-0.428663,"twenty":-2.703896,"median":-1.071184,"eighty":-0.598126,"marketCap":72840589},{"date":"2025-05-09","current":-0.416521,"twenty":-2.69425,"median":-1.060024,"eighty":-0.594913,"marketCap":70777252},{"date":"2025-05-16","current":-0.591746,"twenty":-2.689677,"median":-1.057662,"eighty":-0.591763,"marketCap":84452857},{"date":"2025-05-23","current":-0.639237,"twenty":-2.687748,"median":-1.049056,"eighty":-0.592013,"marketCap":91230678},{"date":"2025-05-30","current":-0.712617,"twenty":-2.684605,"median":-1.046127,"eighty":-0.592742,"marketCap":101703313},{"date":"2025-06-06","current":-0.777592,"twenty":-2.679246,"median":-1.043383,"eighty":-0.594219,"marketCap":110976332},{"date":"2025-06-13","current":-0.711777,"twenty":-2.677429,"median":-1.039863,"eighty":-0.597691,"marketCap":101583351},{"date":"2025-06-20","current":-0.629571,"twenty":-2.675923,"median":-1.039153,"eighty":-0.597691,"marketCap":89851122},{"date":"2025-06-27","current":-0.671514,"twenty":-2.67422,"median":-1.033598,"eighty":-0.596997,"marketCap":95837198},{"date":"2025-07-03","current":-0.617887,"twenty":-2.671808,"median":-1.033598,"eighty":-0.597691,"marketCap":88183658},{"date":"2025-07-11","current":-0.626545,"twenty":-2.667044,"median":-1.033598,"eighty":-0.597691,"marketCap":89419261},{"date":"2025-07-18","current":-0.606624,"twenty":-2.663819,"median":-1.033486,"eighty":-0.596302,"marketCap":86576174},{"date":"2025-07-25","current":-0.680845,"twenty":-2.662803,"median":-1.027334,"eighty":-0.597691,"marketCap":97168770},{"date":"2025-08-01","current":-0.583341,"twenty":-2.658865,"median":-1.025887,"eighty":-0.597691,"marketCap":83253242},{"date":"2025-08-08","current":-0.633438,"twenty":-2.628925,"median":-1.018217,"eighty":-0.597691,"marketCap":90402944},{"date":"2025-08-15","current":-0.671851,"twenty":-2.608646,"median":-1.01456,"eighty":-0.597691,"marketCap":95885182},{"date":"2025-08-22","current":-0.57589,"twenty":-2.594724,"median":-1.009192,"eighty":-0.597691,"marketCap":63423389},{"date":"2025-08-29","current":-1.752501,"twenty":-2.586313,"median":-1.009596,"eighty":-0.598995,"marketCap":193004672},{"date":"2025-09-05","current":-1.765777,"twenty":-2.577902,"median":-1.01456,"eighty":-0.600315,"marketCap":194466829},{"date":"2025-09-12","current":-2.17735,"twenty":-2.562482,"median":-1.018217,"eighty":-0.601664,"marketCap":239793684},{"date":"2025-09-19","current":-2.212754,"twenty":-2.555269,"median":-1.025887,"eighty":-0.603107,"marketCap":243692768},{"date":"2025-09-26","current":-2.018031,"twenty":-2.548721,"median":-1.027334,"eighty":-0.604535,"marketCap":222247805},{"date":"2025-10-03","current":-2.159648,"twenty":-2.542299,"median":-1.033486,"eighty":-0.605723,"marketCap":237844142},{"date":"2025-10-09","current":-2.903133,"twenty":-2.549739,"median":-1.033598,"eighty":-0.605758,"marketCap":319724912}],"updateTime":1760156494931},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IVVD\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2559964065","title":"Invivyd Inc. Announces Rapid Pathway to Approval for COVID-19 Monoclonal Antibody VYD2311 Following FDA Alignment","url":"https://stock-news.laohu8.com/highlight/detail?id=2559964065","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559964065?lang=en_us&edition=fundamental","pubTime":"2025-08-15 04:47","pubTimestamp":1755204451,"startTime":"0","endTime":"0","summary":"Invivyd Inc. has announced its alignment with the U.S. Food and Drug Administration  regarding a streamlined pathway towards potential Biologics License Application  approval for its novel monoclonal antibody candidate, VYD2311, intended for the prevention of COVID-19. This alignment follows a Type C meeting with the FDA, which advised that a single Phase 2/3 randomized, double-blind, placebo-controlled trial could support a BLA submission. The trial will evaluate the efficacy of VYD2311 based on a modest number of RT-PCR-confirmed symptomatic COVID-19 cases. The candidate is targeted for use in individuals aged 12 and older, including those who are immunocompromised. Invivyd plans for a comprehensive trial with a 12-week primary endpoint analysis, assessing the prevention of COVID-19 among a broad population. Pending regulatory alignment, there will also be a planned head-to-head safety evaluation with existing COVID-19 vaccines. Results of the study have not yet been presented.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nNDL5R64RV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4139","LU2210149790.SGD","LU2210150020.SGD","IVVD","LU0314104364.USD","LU2095319765.USD","BK4585","BK4539","IE00B3QW5Z07.USD","BK4588","IE00B64PRP62.GBP","NDAQ","BK4112"],"gpt_icon":0},{"id":"2559964059","title":"Invivyd Aligns With U.S. FDA on Rapid Pathway to Full Approval (Bla) of Vaccine Alternative Monoclonal Antibody Vyd2311 to Protect American Adults and Adolescents From Covid-19","url":"https://stock-news.laohu8.com/highlight/detail?id=2559964059","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559964059?lang=en_us&edition=fundamental","pubTime":"2025-08-15 04:47","pubTimestamp":1755204438,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nTUA7HDSXK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IVVD","BK4539","BK4139"],"gpt_icon":0},{"id":"2557405895","title":"The Race to Find a Measles Treatment as Infections Surge -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2557405895","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557405895?lang=en_us&edition=fundamental","pubTime":"2025-08-08 17:30","pubTimestamp":1754645400,"startTime":"0","endTime":"0","summary":"As a record number of people in the U.S. are sickened with measles, researchers are resurrecting the search for something long-deemed redundant: treatments for the viral disease.After the measles vaccine was introduced in the 1960s, cases of the disease plummeted. By 2000, federal officials had declared measles eliminated from the U.S. This success led to little interest in the development of treatments. But now, as vaccination rates fall and infections rise, scientists are racing to develop drugs they say could prevent or treat the disease in vulnerable and unvaccinated people.Scientists across the country including at biotechs Invivyd and Saravir Biopharma -- and institutions such as Vanderbilt University Medical Center and Georgia State University -- are in the early stages of measles-treatment development. The drugs are still a ways from becoming available to patients but could offer alternatives to people who are immunocompromised, don't respond to the measles vaccine or are vacci","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IVVD","BK4539","BK4139"],"gpt_icon":0},{"id":"2557337113","title":"Invivyd Inc  expected to post a loss of 2 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2557337113","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557337113?lang=en_us&edition=fundamental","pubTime":"2025-08-05 07:24","pubTimestamp":1754349845,"startTime":"0","endTime":"0","summary":"Invivyd Inc  expected to post a loss of2cents a share - Earnings Preview Invivyd Inc IVVD.OQ IVVD.O is expected to  show a rise in quarterly revenue when it reports  results on August 6 (estimated) fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nL8N3TW2Y4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IVVD"],"gpt_icon":0},{"id":"2548896930","title":"Invivyd Inc. Launches SPEAR Study Group to Explore Monoclonal Antibody Therapy for Long COVID and Post-Vaccination Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2548896930","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548896930?lang=en_us&edition=fundamental","pubTime":"2025-07-02 19:01","pubTimestamp":1751454094,"startTime":"0","endTime":"0","summary":"Invivyd, Inc. has announced the formation of the SPEAR Study Group, a clinical and translational study group focused on the effects of monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome. The group will conduct collaborative, multi-center translational clinical research to explore the biology and clinical disease associated with chronic exposure to the SARS-CoV-2 virus or mRNA vaccine-mediated spike protein. The study aims to evaluate the effects of broadly neutralizing anti-SARS-CoV-2 spike protein monoclonal antibody therapy, including Invivyd's next-generation candidates such as VYD2311, in individuals with Long COVID or Post-Vaccination Syndrome. The results of these trials will be presented in the future, as the research is in the planning and execution phase. The study group includes leading investigators such as Dr. Michael Peluso, Dr. Amy Proal, and Dr. David Putrino, who will work alongside Invivyd to design and implement the clinical trials.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nNDL62Wgcj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4585","BK4112","IE00BGHQF748.EUR","BK4139","IVVD","LU2095319765.USD","LU2210149790.SGD","NDAQ","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4539","BK4588"],"gpt_icon":0},{"id":"2546800467","title":"Invivyd Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2546800467","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546800467?lang=en_us&edition=fundamental","pubTime":"2025-06-26 20:25","pubTimestamp":1750940700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IVVD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 26, 2025 08:25 ET (12:25 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IVVD"],"gpt_icon":0},{"id":"2546787911","title":"Invivyd Says Study Shows VYD2311 Well Tolerated as COVID-19 Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2546787911","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546787911?lang=en_us&edition=fundamental","pubTime":"2025-06-26 19:45","pubTimestamp":1750938347,"startTime":"0","endTime":"0","summary":"Invivyd  said Thursday its phase 1/2 clinical data for VYD2311, a monoclonal antibody candidate to prevent and treat COVID-19, was well tolerated with all adverse events deemed unrelated or classified as mild to moderate in severity.After six months at the end of the study, serum concentrations of VYD2311 remained high and were observed to be substantially greater than that of Invivyd's first-generation monoclonal antibody, pemivibart, the company said.Half-life estimates for VYD2311 ranged from 61 days to 76 days as compared with pemivibart estimated half-life of 49 days, potentially providing longer protection and making it more durable, Invivyd said.The company further said it plans to discuss approval pathways for VYD2311 and follow-on COVID-19 monoclonal antibodies with the US Food and Drug Administration early in Q3.Invivyd's shares were up more than 3% in recent premarket activity.Price: 0.73, Change: +0.026, Percent Change: +3.65","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4568","BNTX","BK4535","BK4548","BK4551","BK4139","BK4588","IVVD","BK4539"],"gpt_icon":0},{"id":"2546578426","title":"BRIEF-Invivyd Announces Positive Full Phase 1/2 Clinical Data For Vyd2311","url":"https://stock-news.laohu8.com/highlight/detail?id=2546578426","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546578426?lang=en_us&edition=fundamental","pubTime":"2025-06-26 19:01","pubTimestamp":1750935710,"startTime":"0","endTime":"0","summary":"BRIEF-Invivyd Announces Positive Full Phase 1/2 Clinical Data For Vyd2311June 26 (Reuters) - Invivyd Inc IVVD.O:INVIVYD ANNOUNCES POSITIVE FULL PHASE 1/2 CLINICAL DATA FOR VYD2311, A NEXT GENERATION C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nTUABG2BX8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","IVVD","BK4139"],"gpt_icon":0},{"id":"2546784463","title":"Invivyd Inc. Announces Upcoming FDA Meeting in Early Q3 to Discuss Regulatory Pathways for VYD2311 COVID-19 Monoclonal Antibodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2546784463","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546784463?lang=en_us&edition=fundamental","pubTime":"2025-06-26 19:01","pubTimestamp":1750935676,"startTime":"0","endTime":"0","summary":"Invivyd Inc. Announces Upcoming FDA Meeting in Early Q3 to Discuss Regulatory Pathways for VYD2311 COVID-19 Monoclonal Antibodies. Invivyd, Inc.  has announced that a Type C meeting is scheduled with the FDA for early in the third quarter of 2025 to discuss the registration-directed next steps for its VYD2311 program, a next-generation monoclonal antibody candidate designed to prevent and treat COVID-19. This meeting will focus on the approval pathways for VYD2311 and other follow-on COVID-19 monoclonal antibodies, with particular attention to treatment options for active COVID-19 and prophylaxis for vulnerable populations, including the elderly, immunocompromised individuals, and pediatric populations. Invivyd plans to release additional information about the VYD2311 program throughout 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nNDL4k0FpP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00BKPKM429.USD","IVVD","BK4588","IE00B3QW5Z07.USD","BK4585","BK4539","LU2095319765.USD","LU2210150020.SGD","IE00B64PRP62.GBP","NDAQ","BK4139","IE00BGHQF748.EUR","BK4112"],"gpt_icon":0},{"id":"2539940882","title":"Invivyd Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2539940882","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539940882?lang=en_us&edition=fundamental","pubTime":"2025-05-29 00:22","pubTimestamp":1748449320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IVVD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 28, 2025 12:22 ET (16:22 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IVVD"],"gpt_icon":0},{"id":"2537135544","title":"Invivyd's Pemgarda Added to NCCN Guidelines in Oncology for B-Cell Lymphomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2537135544","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537135544?lang=en_us&edition=fundamental","pubTime":"2025-05-23 19:35","pubTimestamp":1748000158,"startTime":"0","endTime":"0","summary":"Invivyd  said Friday its investigational monoclonal antibody Pemgarda has been added to the National Comprehensive Cancer Network's clinical practice guidelines in oncology for B-cell lymphomas.The product's inclusion in the cancer non-profit's guidelines recognizes it as a potential option for pre-exposure prophylaxis against COVID-19 in patients with B-cell malignancies, the company said.The company's shares were up 10% in recent premarket activity on Friday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4539","IVVD"],"gpt_icon":0},{"id":"2537935067","title":"Invivyd Inc. Engages FDA for Expedited Pathway on COVID-19 Monoclonal Antibody Development Amidst Regulatory Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2537935067","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537935067?lang=en_us&edition=fundamental","pubTime":"2025-05-21 21:30","pubTimestamp":1747834241,"startTime":"0","endTime":"0","summary":"Invivyd Inc. has announced plans to engage with the U.S. Food and Drug Administration  on an expedited pathway to develop next-generation COVID-19 prevention and treatment options. This initiative comes as the FDA acknowledges uncertainties in the efficacy of current COVID-19 vaccine boosters and aligns with Invivyd's Citizen Petition requests. The company aims to advance its monoclonal antibody therapies, including the investigational mAb VYD2311, to provide scalable and high-quality protection against modern immune-evasive SARS-CoV-2 viruses. Invivyd anticipates a clinical update on VYD2311 this quarter, marking a significant step in addressing the ongoing challenges posed by COVID-19, especially for high-risk populations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDL8ZgYWz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4588","BK4539","BK4112","IE00BGHQF748.EUR","BK4139","LU2210150020.SGD","LU2210149790.SGD","BK4585","IVVD","LU2095319765.USD","NDAQ","IE00B64PRP62.GBP","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2536340183","title":"Invivyd Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2536340183","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536340183?lang=en_us&edition=fundamental","pubTime":"2025-05-17 04:10","pubTimestamp":1747426200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IVVD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 16, 2025 16:10 ET (20:10 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IVVD"],"gpt_icon":0},{"id":"2535825011","title":"Invivyd Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2535825011","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535825011?lang=en_us&edition=fundamental","pubTime":"2025-05-15 21:31","pubTimestamp":1747315918,"startTime":"0","endTime":"0","summary":"Invivyd Inc reports results for the quarter ended March 31 - Earnings SummaryInvivyd Inc IVVD.OQ reported a quarterly adjusted loss of 14 cents per share for the quarter ended March 31, higher than th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nL8N3RN1MK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IVVD"],"gpt_icon":0},{"id":"2535845235","title":"Invivyd Q1 EPS $(0.14) Up From $(0.38) YoY, Sales $11.30M Up from 0 YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2535845235","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535845235?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:05","pubTimestamp":1747307125,"startTime":"0","endTime":"0","summary":"Invivyd (NASDAQ:IVVD) reported quarterly losses of $(0.14) per share. This is a 63.16 percent increase over losses of $(0.38) per share from the same period last year.  The company reported $11.30 million in sales this","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45432425/invivyd-q1-eps-0-14-up-from-0-38-yoy-sales-11-30m-up-from-0-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IVVD"],"gpt_icon":0},{"id":"2535845133","title":"Invivyd Inc. Reports Q1 2025 Results: PEMGARDA Revenue at $11.3M, Net Loss Reduced to $16.3M, EPS at $0.14","url":"https://stock-news.laohu8.com/highlight/detail?id=2535845133","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535845133?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:04","pubTimestamp":1747307059,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire  on May 15, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nNDL5DbFy4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IVVD","FCNCA"],"gpt_icon":0},{"id":"2535384567","title":"BRIEF-Invivyd Q1 EPS USD -0.14","url":"https://stock-news.laohu8.com/highlight/detail?id=2535384567","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535384567?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:01","pubTimestamp":1747306905,"startTime":"0","endTime":"0","summary":"BRIEF-Invivyd Q1 EPS USD -0.14\n\n\nMay 15 (Reuters) - Invivyd Q1 revenue USD 11.304 million.\n\nQ1 net income USD -16.289 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nPLXF72938:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IVVD"],"gpt_icon":0},{"id":"2535029018","title":"Invivyd Urges US FDA to Focus on Monoclonal Antibodies for COVID-19 Prevention, Re-Assess Vaccine Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2535029018","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535029018?lang=en_us&edition=fundamental","pubTime":"2025-05-14 20:35","pubTimestamp":1747226134,"startTime":"0","endTime":"0","summary":"Invivyd (IVVD) said Wednesday that it has urged the US Food and Drug Administration to focus on monoclonal antibodies for the prevention of COVID-19 to rebuild Americans' trust in scientific data and ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4535","BK4585","BK4539","BK4568","BK4548","BNTX","IVVD","BK4139","BK4551","BK4588"],"gpt_icon":0},{"id":"2535708298","title":"Invivyd Inc  expected to post a loss of 3 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2535708298","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535708298?lang=en_us&edition=fundamental","pubTime":"2025-05-13 22:52","pubTimestamp":1747147925,"startTime":"0","endTime":"0","summary":"Invivyd Inc  expected to post a loss of3cents a share - Earnings Preview Invivyd Inc IVVD.OQ IVVD.O is expected to show a rise in quarterly revenue when it reports  results on May 15 for the period en","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nL8N3RL1ZS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Invivyd Inc  expected to post a loss of 3 cents a share - Earnings Preview","news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IVVD"],"gpt_icon":0},{"id":"2535001562","title":"BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers Health, TXNM Energy, Forge Global","url":"https://stock-news.laohu8.com/highlight/detail?id=2535001562","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535001562?lang=en_us&edition=fundamental","pubTime":"2025-05-13 01:45","pubTimestamp":1747071945,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers Health, TXNM Energy, Forge GlobalEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250512:nL6N3RK0H2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TECH","CHWY","DE","DHR","EOG","CE","IVVD","QMCO","QDEL","GOGL","TXNM","UAA","MAT","SG","NEM","BAC","FCX","MBRX","EQT","IBRX","TMO","LNG","CSX","AXP","MAN","FRGE","BLDE","LOW","MODV","ISRG","SCCO","XOM","GEHC","LNT","SGI","CNH","HAS","WSM"],"gpt_icon":1}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":63,"code":"91000000","status":"200"}]}}